Quantcast

Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma - KOAM TV 7

Biotech Stocks on our Radar -- Research on ImmunoGen, Idenix Pharma, Repligen, and Vanda Pharma

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Investor-Edge

Editor Note: For more information about this release, please scroll to bottom.

LONDON, May 9, 2014 /PRNewswire/ --

On Thursday, May 08, 2014, the NASDAQ Composite ended at 4,051.50, down 0.40%, the Dow Jones Industrial Average finished the session at 16,550.97, up 0.20% and the S&P 500 closed at 1,875.63, down 0.14%. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 664.48, down 0.53%, while the index has gained 0.78% in the previous one month. Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Idenix Pharmaceuticals Inc. (NASDAQ: IDIX), Repligen Corp. (NASDAQ: RGEN) and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA). Free technical research on IMGN, IDIX, RGEN and VNDA can be downloaded upon signing up at:

http://www.investor-edge.com/2334-register

ImmunoGen Inc.'s stock fell by 3.65% on Thursday, closing the day at $11.09. The stock recorded a trading volume of 0.71 million shares, which was below its three months average volume of 0.91 million shares. The stock oscillated between $11.05 and $11.80 during the session. Over the previous three trading sessions and in the last one month, ImmunoGen Inc.'s shares have lost 7.58% and 19.87%, respectively. Also, the stock has declined 24.40% from the beginning of 2014. The company's shares are trading below their 50-day and 200-day moving averages. ImmunoGen Inc.'s 50-day moving average of $14.63 is below its 200-day moving average of $15.69. Further, the company's stock has a Relative Strength Index (RSI) of 32.49. Sign up today to read free research on IMGN at:

http://www.investor-edge.com/2334-IMGN-09May2014.pdf

On Thursday, shares in Idenix Pharmaceuticals Inc. recorded a trading volume of 0.80 million shares, which was below its three months average volume of 1.31 million shares. The stock ended the day at $4.94, which was 3.52% lower than its previous day's closing of $5.12, and registered an intraday range of $4.91 and $5.27. Shares in Idenix Pharmaceuticals Inc. have declined 6.08% in the previous three trading sessions, 15.27% in the last one month and 17.39% on YTD basis. The company's stock is trading below its 50-day and 200-day moving averages of $6.16 and $5.47, respectively. Furthermore, shares of the company have an RSI of 40.39. Sign up today to read free research on IDIX at:

http://www.investor-edge.com/2334-IDIX-09May2014.pdf

Repligen Corp.'s stock finished Thursday's trading session 1.83% higher at $17.29, also hitting a new 52-week high of $19.97. A total of 1.31 million shares were traded, above its three months average volume of 0.65 million shares. The stock moved between $16.70 and $19.97 during the session. Repligen Corp.'s stock has gained 4.47% in the previous three trading sessions and 27.60% in the last one month. Moreover, the stock has surged 26.76% since the start of this year. The company's shares are trading above their 50-day and 200-day moving averages of $14.81 and $12.63, respectively. Additionally, the company's stock traded at a PE ratio of 29.23 and has an RSI of 67.73. Sign up today to read free research on RGEN at:

http://www.investor-edge.com/2334-RGEN-09May2014.pdf

Shares in Vanda Pharmaceuticals Inc. fluctuated between $9.52 and $12.40 before ending the session 20.47% lower at $10.14. On Thursday, the company's stock reported a trading volume of 5.18 million shares, much above its three months average volume of 1.16 million shares. Over the previous three trading sessions and in the last one month, shares in Vanda Pharmaceuticals Inc. have fallen by 27.78% and 32.26%, respectively. Also, the stock has declined 18.29% on YTD basis. On the same day, Vanda Pharmaceuticals Inc. announced its Q1 2014 financial results. The company reported that its total revenues for Q1 2014 stood at $9.1 million, compared with the revenues of $8.1 million in the year-ago quarter. In addition, the company reported a net loss of $26.5 million for the Q1 2014, compared to with a net loss of $4.5 million in Q1 2013. Sign up today to read free research on VNDA at:

http://www.investor-edge.com/2334-VNDA-09May2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

KOAM - Licensed to Pittsburg, Kansas
Send tips, ideas and press releases to: tips@koamtv.com
Send newsroom questions or comments to: comments@koamtv.com
Phone: (417) 624-0233 or (620) 231-0400
Web comments or questions: webmaster@koamtv.com
Newsroom Fax: (417) 624-3158

Powered by WorldNow All content © Copyright 2000 - 2014 WorldNow and KOAM. All Rights Reserved. For more information on this site, please read our Privacy Policy and Terms of Service.